
Studies have suggested that zzso has shown activity against various pediatric solid zzso zzso therefore, conducted a Phase I study of zzso plus zzso in Japanese children with zzso progressive or zzso solid zzso 

The starting dose was zzso 10 zzso over zzso zzso and zzso 125 zzso over 90 zzso zzso on Days 1, 15 and zzso The dose of zzso was 340 zzso for patients receiving zzso zzso zzso Treatment was repeated every 6 weeks for up to three courses in the absence of disease progression or unacceptable zzso 

Of 11 patients, 9 zzso age, 9 zzso were fully zzso for toxicity and received 24 zzso zzso zzso were Grade 2 zzso and Grade 4 zzso in two of the five patients at dose level zzso No zzso zzso were observed in four patients at dose level zzso at zzso 10 zzso and zzso 100 zzso zzso zzso for patients taking zzso zzso zzso The zzso dose was zzso 10 zzso and zzso 100 zzso The most frequent zzso zzso were Grade 1 or 2 hypertension, bleeding and zzso zzso One patient with zzso nerve zzso had a partial zzso Three patients with zzso zzso nerve zzso and diffuse intrinsic zzso zzso had stable zzso 

Combination chemotherapy of zzso plus zzso was well tolerated in zzso We plan Phase II pediatric studies at doses of zzso 10 zzso and zzso 100 zzso every 2 weeks zzso zzso for patients taking zzso zzso zzso 

